Press Releases

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 4, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 15 th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD

- The launch of this campaign is about imagining a future where ongoing research, support, and heightened disease awareness for people with extremely high triglycerides come together to change lives — 'We'll Get There Soon' PASADENA, Calif. --(BUSINESS WIRE)--Nov.

PASADENA, Calif. --(BUSINESS WIRE)--Oct. 14, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024 , the Company’s Board of Directors approved “inducement” grants to 34 new employees under Rule

- In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif. --(BUSINESS WIRE)--Sep. 23, 2024-- Arrowhead Pharmaceuticals, Inc.

PALISADE Phase 3 results demonstrate plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83% in patients with genetically confirmed and clinically diagnosed FCS 1 PASADENA, Calif. --(BUSINESS WIRE)--Sep.

- Plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83% - Similar responses were observed in patients with genetically confirmed and clinically diagnosed FCS - Based on these findings, Arrowhead plans to file a New Drug Application by

- Company hosting a virtual analyst and investor event on September 3, 2024 , at 8:00 am EDT to discuss results PASADENA, Calif. --(BUSINESS WIRE)--Aug. 21, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study

- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024 , at 2:00 pm ET as Part IV of the 2024 Summer Series of R&D Webinars PASADENA, Calif. --(BUSINESS WIRE)--Aug. 14, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans

- Conference Call and Webcast Today, August 8, 2024 , at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 8, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024 .

- Balance sheet strengthened with long-term, non-dilutive capital - $400 million funded at close with the potential to draw an additional $100 million - Immediately enhances Arrowhead’s ability to advance plozasiran towards a 2025 launch - Expands possibilities to fund innovation and growth across